Marisa Wexler, MS,  senior science writer—

Treatment with regulatory T-cells, or Tregs — a type of anti-inflammatory immune cell — was well tolerated and seemed to slow disease progression in a small clinical trial that enrolled six people with amyotrophic lateral sclerosis (ALS). The work was conducted by scientists at Columbia University in New…

A combination of three drugs — one of them the experimental therapy CuATSM — may be effective for treating amyotrophic lateral sclerosis (ALS) caused by mutations in the SOD1 gene, according to a new preclinical study. In mice carrying SOD1 mutations, the combination of these three drugs — CuATSM,…

A rare mutation that leads to abnormally high activity of the CREB3 protein is associated with a reduced risk of developing amyotrophic lateral sclerosis (ALS) and people with ALS who carry this mutation progress significantly more slowly and live longer than those who don’t. That’s according to the study,…

Scientists have developed a novel method to efficiently grow motor neurons from skin cells, which may serve as a platform for creating cell therapies to treat diseases like amyotrophic lateral sclerosis (ALS). The new method was described in two papers — one titled “Compact transcription factor cassettes…

A bipartisan team of lawmakers in the U.S. House of Representatives and Senate is pushing for legislation to help ensure that spouses of veterans who die from amyotrophic lateral sclerosis (ALS) have access to benefits. The Justice for ALS Veterans Act was introduced in the House by Brian Fitzpatrick,…

Measuring blood levels of neurofilament light chain, or NfL, a biomarker of nerve damage, may help in diagnosing amyotrophic lateral sclerosis (ALS), and in predicting the risk of death among people with the neurodegenerative condition, a new study shows. This biomarker showed substantially better accuracy for both ALS diagnosis…

Fat molecules called polyunsaturated fatty acids, or PUFAs, can help lessen nerve damage in amyotrophic lateral sclerosis (ALS), according to a study of fruit flies and cell models. Previous studies have shown that consumption of omega-3 fatty acid, a type of PUFA, is associated with a lower risk…

Four experimental treatments for amyotrophic lateral sclerosis (ALS) have been tested in the HEALEY ALS platform trial and two, CNM-Au8 and pridopidine, have shown promising results and are moving toward Phase 3 testing. The others, zilucoplan and verdiperstat, failed to show any benefit and are no…

Sleep problems may become evident in people with amyotrophic lateral sclerosis (ALS) several years before the characteristic motor symptoms of the disease develop, a new study shows. The study suggests alterations in a brain region called the hypothalamus, which are seen in early disease stages and sometimes even…

Oral therapy IFB-088 (icerguastat) was safe and significantly slowed disease progression in certain people with amyotrophic lateral sclerosis (ALS), according to new data from a Phase 2 clinical trial. “We are very encouraged by the results we observed with IFB-088,” Pierre Miniou, CEO of IFB-088’s developer Inflectis Bioscience,…